Chicagoland Diabetes TrialNet Clinical Center

芝加哥糖尿病 TrialNet 临床中心

基本信息

  • 批准号:
    8774722
  • 负责人:
  • 金额:
    $ 37.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-05 至 2017-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This application "Chicagoland TrialNet Clinical Center" is in response to the RFA -DK-13-010 Type 1 Diabetes TrialNet Clinical Centers (U01). Here we describe a joint effort from the University of Chicago and Advocate Children's Hospital (ACH) sites (Park Ridge and Oak Lawn, Illinois) and Advocate Health Care (AHC) to create a new Clinical Center in the Chicagoland area. These organizations along with our other affiliate (Lurie Children's Hospital) and partner sites saw over 9000 patients with type 1 diabetes (T1D) in 2012. Together, these practice sites along with other participating key adult and pediatric diabetes practitioners from Chicago reach over 12 million individuals within a two-hour drive of a screening location. The Chicago community, strong supporters of the Juvenile Diabetes Research Foundation (JDRF) and American Diabetes Association (ADA), has been under-represented in clinical trials for Type 1 Diabetes (T1D). This partnership will bring together the resources of major medical centers committed to T1D research and clinical care to reach more of the estimated 100,000 individuals with T1D in the Chicagoland area (about 0.8% of the area population) and their families, as well as the 2000 projected new cases of T1D and their families each year. This outreach will involve diverse communities from some of the wealthiest to some of the most underserved in the United States. We will build on our success in creating the largest database for monogenic diabetes in the United States. We will engage the greater Chicagoland community through innovative social media and direct communications combining media support, direct visits to local practices, community events supported by our institutions and partners and outreach to large networks of faith communities. The University of Chicago has been committed to diabetes research for over 100 years, and together with Advocate Children's Hospital and other partners we will bring a new sense of energy, organization, and purpose to TrialNet recruitment and screening in the Chicagoland region.
描述(由申请人提供):本申请“芝加哥TrialNet临床中心”是对RFA -DK-13-010 1型糖尿病TrialNet临床中心(U 01)的回应。在这里,我们描述了一个共同的努力,从芝加哥和倡导儿童医院(ACH)网站(公园岭和橡树草坪,伊利诺伊州)和倡导卫生保健(AHC)在芝加哥地区创建一个新的临床中心。2012年,这些组织沿着我们的其他附属机构(Lurie儿童医院)和合作机构共接诊了9000多名1型糖尿病(T1 D)患者。总之,这些实践地点沿着其他参与的关键成人和儿科糖尿病从业人员从芝加哥达到超过1200万人在两个小时的车程内的筛选位置。芝加哥社区是青少年糖尿病研究基金会(JDRF)和美国糖尿病协会(ADA)的坚定支持者,在1型糖尿病(T1 D)的临床试验中代表性不足。该合作伙伴关系将汇集致力于T1 D研究和临床护理的主要医疗中心的资源,以覆盖芝加哥地区约10万T1 D患者(约占该地区人口的0.8%)及其家庭,以及每年预计的2000例T1 D新病例及其家庭。这一外联活动将涉及不同的社区,从美国最富有的一些社区到最缺乏服务的一些社区。我们将在成功创建美国最大的单基因糖尿病数据库的基础上再接再厉。我们将通过创新的社交媒体和直接沟通,结合媒体支持,直接访问当地的做法,由我们的机构和合作伙伴支持的社区活动,以及与大型信仰社区网络的联系,来参与更大的芝加哥社区。芝加哥大学100多年来一直致力于糖尿病研究,与Advocate儿童医院和其他合作伙伴一起,我们将为芝加哥地区的TrialNet招募和筛查带来新的活力,组织和目的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Louis H. Philipson其他文献

Ion Channels, Action Potentials and Ca<sup>2+</sup> Handling in Human Pancreatic Beta-Cells. a Computational Approach
  • DOI:
    10.1016/j.bpj.2010.12.696
  • 发表时间:
    2011-02-02
  • 期刊:
  • 影响因子:
  • 作者:
    Leonid E. Fridlyand;Louis H. Philipson
  • 通讯作者:
    Louis H. Philipson
An online monogenic diabetes discussion group: supporting families and fueling new research
  • DOI:
    10.1016/j.trsl.2015.06.013
  • 发表时间:
    2015-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Marie E. Perrone;David Carmody;Louis H. Philipson;Siri Atma W. Greeley
  • 通讯作者:
    Siri Atma W. Greeley
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis
  • DOI:
    10.1007/s11606-021-07105-9
  • 发表时间:
    2021-09-10
  • 期刊:
  • 影响因子:
    4.200
  • 作者:
    Jason T. Alexander;Erin M. Staab;Wen Wan;Melissa Franco;Alexandra Knitter;M. Reza Skandari;Shari Bolen;Nisa M. Maruthur;Elbert S. Huang;Louis H. Philipson;Aaron N. Winn;Celeste C. Thomas;Meltem Zeytinoglu;Valerie G. Press;Elizabeth L. Tung;Kathryn Gunter;Brittany Bindon;Sanjay Jumani;Neda Laiteerapong
  • 通讯作者:
    Neda Laiteerapong
The Two-Pore-Domain Potassium Channels, TASK-1 and TASK-3, regulate Pancreatic Beta-Cell Membrane Potential in Response to pH and Anesthetics
  • DOI:
    10.1016/j.bpj.2010.12.743
  • 发表时间:
    2011-02-02
  • 期刊:
  • 影响因子:
  • 作者:
    Prasanna Dadi;Louis H. Philipson;David A. Jacobson
  • 通讯作者:
    David A. Jacobson
Dynamin Function in Exocytosis and Endocytosis Coupling of Dense-Core Vesicles in Pancreatic Beta Cells
  • DOI:
    10.1016/j.bpj.2019.11.2700
  • 发表时间:
    2020-02-07
  • 期刊:
  • 影响因子:
  • 作者:
    Fan Fan;Jenifer Wendlick;Natalia Tamarina;Yumei Wu;Shawn Ferguson;Louis H. Philipson;Pietro De Camilli;Xuelin Lou
  • 通讯作者:
    Xuelin Lou

Louis H. Philipson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Louis H. Philipson', 18)}}的其他基金

Center for Identification and Study of Individuals with Atypical Diabetes Mellitus
非典型糖尿病个体识别和研究中心
  • 批准号:
    10660917
  • 财政年份:
    2018
  • 资助金额:
    $ 37.17万
  • 项目类别:
Chicagoland Diabetes TrialNet Clinical Center
芝加哥糖尿病 TrialNet 临床中心
  • 批准号:
    9414298
  • 财政年份:
    2014
  • 资助金额:
    $ 37.17万
  • 项目类别:
Chicagoland Diabetes TrialNet Clinical Center
芝加哥糖尿病 TrialNet 临床中心
  • 批准号:
    9065721
  • 财政年份:
    2014
  • 资助金额:
    $ 37.17万
  • 项目类别:
Core A: Islet Cell Biology Core
核心 A:胰岛细胞生物学核心
  • 批准号:
    8626377
  • 财政年份:
    2014
  • 资助金额:
    $ 37.17万
  • 项目类别:
Core A: Islet Cell Biology Core
核心 A:胰岛细胞生物学核心
  • 批准号:
    8446544
  • 财政年份:
    2013
  • 资助金额:
    $ 37.17万
  • 项目类别:
K+ Channel Expression in Pancreatic Beta-Cells
胰腺 β 细胞中 K 通道的表达
  • 批准号:
    8006768
  • 财政年份:
    2010
  • 资助金额:
    $ 37.17万
  • 项目类别:
Diabetes Research and Training Center
糖尿病研究与培训中心
  • 批准号:
    7500638
  • 财政年份:
    2006
  • 资助金额:
    $ 37.17万
  • 项目类别:
ISLET CELL BIOLOGY CORE
胰岛细胞生物学核心
  • 批准号:
    7660174
  • 财政年份:
    2005
  • 资助金额:
    $ 37.17万
  • 项目类别:
INSULIN SECREETION IN ISLET CELL TRANSPLANT RECIPIENTS
胰岛细胞移植受者的胰岛素分泌
  • 批准号:
    7201053
  • 财政年份:
    2005
  • 资助金额:
    $ 37.17万
  • 项目类别:
Pediatric Endocrinology Research Training Grant
儿科内分泌学研究培训补助金
  • 批准号:
    8867222
  • 财政年份:
    2004
  • 资助金额:
    $ 37.17万
  • 项目类别:

相似海外基金

Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
  • 批准号:
    10760051
  • 财政年份:
    2023
  • 资助金额:
    $ 37.17万
  • 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
  • 批准号:
    2303692
  • 财政年份:
    2023
  • 资助金额:
    $ 37.17万
  • 项目类别:
    Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
  • 批准号:
    468168
  • 财政年份:
    2022
  • 资助金额:
    $ 37.17万
  • 项目类别:
    Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10427960
  • 财政年份:
    2022
  • 资助金额:
    $ 37.17万
  • 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
  • 批准号:
    10577074
  • 财政年份:
    2022
  • 资助金额:
    $ 37.17万
  • 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
  • 批准号:
    486588
  • 财政年份:
    2022
  • 资助金额:
    $ 37.17万
  • 项目类别:
    Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
  • 批准号:
    2760091
  • 财政年份:
    2022
  • 资助金额:
    $ 37.17万
  • 项目类别:
    Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
  • 批准号:
    10621188
  • 财政年份:
    2022
  • 资助金额:
    $ 37.17万
  • 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
  • 批准号:
    10891016
  • 财政年份:
    2021
  • 资助金额:
    $ 37.17万
  • 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
  • 批准号:
    10230365
  • 财政年份:
    2020
  • 资助金额:
    $ 37.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了